UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K



                                 CURRENT REPORT


                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934


         Date of Report (Date of Earliest Event Reported): May 22, 2002


                         Shire Pharmaceuticals Group plc
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                                England and Wales
--------------------------------------------------------------------------------
                 (State or other jurisdiction of incorporation)


              0-29630                                    98-0359573
-------------------------------------      -------------------------------------
     (Commission File Number)                (IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
Hampshire RG24 8EP England
--------------------------------------------------------------------------------
(Address of principal executive offices)                           (Zip code)

Registrant's telephone number, including area code         44 1256 894 000
                                                  ------------------------------



--------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)







Item 5.  Other Events

     On May 22, 2002, Shire Pharmaceuticals Group plc gave a presentation, the
transcript of which is attached hereto as Exhibit 99.1 and incorporated by
reference herein, at an investors meeting held in Philadelphia, Pennsylvania.

Item 7.  Financial Statements and Exhibits

     (c) Exhibits. The following exhibit is filed herewith:

          99.1 Transcript of Investor Presentation dated May 22, 2002.






                                      -2-



                                    SIGNATURE


     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated:  May 23, 2002           SHIRE PHARMACEUTICALS GROUP PLC



                               By:    /s/ Angus Charles Russell
                                      ------------------------------------------
                                      Name:  Angus Charles Russell
                                      Title:  Group Finance Director







                                  EXHIBIT INDEX


Number   Description

99.1              Transcript of Investor Presentation dated May 22, 2002.